386 related articles for article (PubMed ID: 24395704)
1. Mutant TP53 posttranslational modifications: challenges and opportunities.
Nguyen TA; Menendez D; Resnick MA; Anderson CW
Hum Mutat; 2014 Jun; 35(6):738-55. PubMed ID: 24395704
[TBL] [Abstract][Full Text] [Related]
2. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.
McCubrey JA; Lertpiriyapong K; Fitzgerald TL; Martelli AM; Cocco L; Rakus D; Gizak A; Libra M; Cervello M; Montalto G; Yang LV; Abrams SL; Steelman LS
Adv Biol Regul; 2017 Jan; 63():32-48. PubMed ID: 27776972
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
[TBL] [Abstract][Full Text] [Related]
4. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Pfister NT; Prives C
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
[TBL] [Abstract][Full Text] [Related]
6. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
7. Friend or Foe: MicroRNAs in the p53 network.
Luo Z; Cui R; Tili E; Croce C
Cancer Lett; 2018 Apr; 419():96-102. PubMed ID: 29330109
[TBL] [Abstract][Full Text] [Related]
8.
Coan M; Toso M; Cesaratto L; Rigo I; Borgna S; Dalla Pietà A; Zandonà L; Iuri L; Zucchetto A; Piazza C; Baldassarre G; Spizzo R; Nicoloso MS
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762037
[No Abstract] [Full Text] [Related]
9. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
10. The regulation of radiosensitivity by p53 and its acetylation.
Zhang J; Shen L; Sun LQ
Cancer Lett; 2015 Jul; 363(2):108-18. PubMed ID: 25911240
[TBL] [Abstract][Full Text] [Related]
11. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
12. ROS modifiers and NOX4 affect the expression of the survivin-associated radio-adaptive response.
Murley JS; Arbiser JL; Weichselbaum RR; Grdina DJ
Free Radic Biol Med; 2018 Aug; 123():39-52. PubMed ID: 29660403
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 in cancer: new functions and therapeutic opportunities.
Muller PA; Vousden KH
Cancer Cell; 2014 Mar; 25(3):304-17. PubMed ID: 24651012
[TBL] [Abstract][Full Text] [Related]
14. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
15. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
17. Histone modifications affect differential regulation of TGFβ- induced NADPH oxidase 4 (NOX4) by wild-type and mutant p53.
Boudreau HE; Ma WF; Korzeniowska A; Park JJ; Bhagwat MA; Leto TL
Oncotarget; 2017 Jul; 8(27):44379-44397. PubMed ID: 28574838
[TBL] [Abstract][Full Text] [Related]
18. The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.
Singh S; Kumar M; Kumar S; Sen S; Upadhyay P; Bhattacharjee S; M N; Tomar VS; Roy S; Dutt A; Kundu TK
J Biol Chem; 2019 Sep; 294(38):14081-14095. PubMed ID: 31366730
[TBL] [Abstract][Full Text] [Related]
19. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]